Hindustan Bio Sciences
HINDUSTANBIOSCIENCESLTD NSE
Hindustan Bio Sciences
Information TechnologyNSE: HINDUSTANBIOSCIENCESLTD BSE: 532041 Software Products
Key Fundamentals
MicrocapSoftware ProductsInformation TechnologyMarket Cap
₹7.84 Cr
Volatility
Moderate
P/E Ratio
-39.8
EBITDA
₹-0.06 Cr
Return on Equity
11.13%
Debt to Equity
2.83
Book Value
₹0.81
EPS
₹0.25
52W High
₹9.92
52W Low
₹5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Debtor days have improved from 125 to 24.7 days.
Weaknesses
6- Stock is trading at 9.93 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.40% over past five years.
- Promoter holding is low: 12.2%
- Company has a low return on equity of 3.21% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
-7.5% lower than
3Y
Net Income Growth
-180% level than
3Y
Cash Flow Change
102% lower than
3Y
ROE
55.45% higher than
3Y
ROCE
71.76% higher than
3Y
EBITDA Margin (Avg.)
-166% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0.32 | 0.32 | 0.39 | 0.41 | 0.41 | 0 | 0.38 | 0.32 | 0 | 0.38 | 0 | 0 |
| Expenses | 0.12 | 0.26 | 0.26 | 0.35 | 0.34 | 0.34 | 0.04 | 0.28 | 0.32 | 0.06 | 0.31 | 0.11 | 0.11 |
| Operating Profit | -0.12 | 0.06 | 0.06 | 0.04 | 0.07 | 0.07 | -0.04 | 0.1 | 0 | -0.06 | 0.07 | -0.11 | -0.11 |
| OPM % | — | 18.75% | 18.75% | 10.26% | 17.07% | 17.07% | — | 26.32% | 0% | — | 18.42% | — | — |
| Other Income | 0 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.02 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 |
| PBT | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | 0.08 | -0.04 | 0.11 | 0.01 | -0.05 | 0.08 | -0.11 | -0.11 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | 0.08 | -0.04 | 0.11 | 0.01 | -0.06 | 0.08 | -0.12 | -0.11 |
| EPS in Rs | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | 0.08 | -0.04 | 0.11 | 0.01 | -0.06 | 0.08 | -0.12 | -0.11 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.74 | 0.38 |
| Expenses | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.8 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.8 | 0.59 |
| Operating Profit | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.1 | -0.06 | -0.21 |
| OPM % | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.6% | -3.26% | 5.71% | 12.35% | -8.11% | -55.26% |
| Other Income | -0.01 | -1.92 | 0 | 0.09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 |
| Interest | 0.03 | 0.03 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0.02 | 0.01 |
| PBT | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.1 | -0.08 | -0.19 |
| Tax % | 0.69% | 0% | 0% | 0% | 0% | 33.33% | -2.08% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.1 | -0.08 | -0.21 |
| EPS in Rs | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.1 | -0.08 | -0.21 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 | 2.05 |
| Reserves | -3.34 | -5.43 | -5.92 | -8.2 | -8.09 | -8.01 | -8.95 | -9.46 | -1.3 | -1.25 | -1.15 | -1.22 |
| Borrowings | 0.97 | 0.94 | 1.3 | 1.57 | 3.37 | 2.6 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 | 2.35 |
| Other Liabilities | 0.17 | 0.12 | 0.24 | 0.09 | 0.1 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 | 0.02 |
| Total Liabilities | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.2 |
| Fixed Assets | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 |
| CWIP | 1.92 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.5 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 | 3.19 |
| Total Assets | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.2 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.27 | 0.46 | -0.16 | -0.23 | -1.32 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 | 0.03 | 0.28 |
| Investing | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | -0.01 |
| Financing | 0.3 | -0.63 | 0.18 | 0.21 | 1.5 | -0.81 | -0.93 | 0.34 | 0.05 | 1.43 | -0.05 | -0.16 |
| Net Cash Flow | 0.03 | -0.17 | 0.01 | -0.02 | 0.17 | 0.01 | -0.18 | -0.01 | 0 | 0.03 | -0.02 | 0.12 |
| Free Cash Flow | -0.27 | 0.46 | -0.16 | -0.23 | -1.33 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 | 0.03 | 0.27 |
| CFO/OP | 22 | -383 | 34 | 10 | -1,015 | 600 | -78 | 67 | 167 | -2,350 | 30 | -467 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 156 | 136 | 170 | 113 | 171 | 256 | 220 | 119 | 179 | 153 | 198 | 24.66 |
| Inventory Days | 25.08 | 0 | 0 | 51.23 | 13.89 | 95.46 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payable | 39.01 | — | — | 44.82 | 7.58 | 185 | — | — | — | — | — | — |
| Cash Conversion Cycle | 142 | 136 | 170 | 120 | 178 | 166 | 220 | 119 | 179 | 153 | 198 | 24.66 |
| Working Capital Days | 112 | -63.73 | -192 | -170 | 85.1 | 86.55 | -149 | -501 | -226 | 313 | 442 | 306 |
| ROCE % | -16.4% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.3% | 1.52% | 2.95% | -2.43% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Hindustan Bio Sciences insights
61 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with the Regulation 74(5) of SEBI(Depositories and Participants) Regulation, 2018 for the Fourth … 14 Apr - Certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with the Regulation 74(5) of SEBI(Depositories and Participants) Regulation, 2018 for the Fourth …
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5h - KPI Green Energy Limited informed Exchange regarding its participation in the Analyst(s)/Institutional Investor(s) Meet, scheduled to be held on March 11, 2026. Detailed disclosure is … 5h - KPI Green Energy Limited informed Exchange regarding its participation in the Analyst(s)/Institutional Investor(s) Meet, scheduled to be held on March 11, 2026. Detailed disclosure is …
4
Completion Of 92.4 MW Wind Power Project For Ayana Renewable Power Four
20 Feb - Completed 92.4 MW wind project for Ayana at Nakhatrana, Bhuj (28 WTGs); CEA approval received. 20 Feb - Completed 92.4 MW wind project for Ayana at Nakhatrana, Bhuj (28 WTGs); CEA approval received.
Frequently Asked Questions about Hindustan Bio Sciences
What does Hindustan Bio Sciences Ltd do?
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products.[1]
Where is Hindustan Bio Sciences Ltd (532041) listed?
Hindustan Bio Sciences Ltd trades as HINDUSTANBIOSCIENCESLTD on the NSE and under code 532041 on the BSE.
Which sector does Hindustan Bio Sciences Ltd belong to?
Hindustan Bio Sciences Ltd is classified under the Information Technology sector, in the Software Products industry.
What is the market capitalisation of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd has a market capitalisation of ₹7.84 Cr, which places it in the Small Cap band.
What is the PE ratio of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd trades at a PE ratio of -39.80, on earnings per share of ₹0.25, against a book value of ₹0.81 per share.
What is the 52-week high and low of Hindustan Bio Sciences Ltd?
Over the last 52 weeks Hindustan Bio Sciences Ltd has traded between ₹5 and ₹9.92.
What is the Return on Equity (ROE) of Hindustan Bio Sciences Ltd?
Hindustan Bio Sciences Ltd reported a return on equity of 11.13%. Its debt-to-equity ratio is 2.83.
Company Information
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products.[1]
Website hindustanbiosciences.in
Face Value ₹ 2
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532041.md for Hindustan Bio Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.